HyFaCol
HyFaCol provides a collagen manufacturing platform that produces medical-grade collagen for advanced wound care and guided bone regeneration (GBR) markets. The company's patented processes create GBR membranes that last 50% longer than current gold-standard products, reducing the need for additional surgeries. The platform addresses issues that prevent nearly 90% of the advanced wound dressing market from adopting collagen-based solutions.
- New Materials
- Biotechnology
- Healthcare Technology
- Medical Devices
- Manufacturing / Industry 4.0
- Hardware
Funding
Founders
Founder details are not available yet.
Product
Problem
Currently available collagen-based wound and bone-related products suffer from uncontrollable swelling, poor mechanical properties, and fast breakdown, leading to unsatisfactory clinical outcomes, additional healthcare costs, and diminished quality of life for patients. These issues also reduce clinician confidence and adoption, restricting industry growth in the medical-grade collagen market.
Solution
HyFaCol provides a collagen manufacturing platform that significantly improves the production and quality of medical-grade collagen for the advanced wound care and guided bone regeneration (GBR) markets. The platform employs bespoke, patented manufacturing processes to create wound dressings and GBR membranes with superior clinical performance, including membranes that last 50% longer than the current gold standard. This patient-focused approach reduces treatment timeframes and the number of treatment attempts, lowering overall healthcare costs while offering clinicians a more reliable treatment option that increases adoption of collagen-based solutions.
Target Audience
Primary customers are healthcare professionals and medical device companies operating in the advanced wound care and guided bone regeneration markets, including clinicians seeking more reliable collagen-based treatment options for patients.
Features
- Patented manufacturing processes developed over ten years of research for medical-grade collagen production
- GBR membranes with 50% longer durability compared to current gold-standard products, minimizing risks of additional surgery
- Wound dressings engineered to address the issues preventing nearly 90% of the advanced wound dressing market from adopting collagen-based solutions
- Bespoke manufacturing routes designed for industrial scalability in medical textile applications
- Technology applicable to both collagen-based and non-collagen-based wound dressing and GBR markets
- Patents already granted in key markets of the EU and US